Category Archives: Regenerative Medicine

CANTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for its third quarter ended September 30, 2019.

Third Quarter 2019 Financial Summary:

Third Quarter 2019 and Recent Highlights:

We delivered another quarter of significant year-over-year revenue growth across both our Advanced Wound Care and Surgical and Sports Medicine portfolios, said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. We grew our customer base across both portfolios and leveraged PuraPlys pass through advantage to gain new accounts, drive PuraPly adoption deeper into existing accounts and drive sales of our non-PuraPly products to existing PuraPly accounts. Strong execution also drove year-over-year growth of commercially available non-PuraPly products across our customer base. I am very pleased that despite amniotic capacity constraints, we successfully leveraged our diversified portfolio to deliver a solid quarter.

Mr. Gillheeney, Sr. continued: With continued execution against our PuraPly commercial strategy and improved amniotic capacity exiting Q3, we expect a strong finish to the year. We have updated our full-year 2019 revenue guidance and now expect to grow in a range of 31% to 34%. We remain committed to delivering on our mission to provide integrated healing solutions that substantially improve medical outcomes while lowering the overall cost of care.

READ THE REST HERE

More:
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results - OrthoSpineNews

Topline results expected before the end of Q1/2020

Rehovot, Israel and New York, NY (GLOBE NEWSWIRE) - Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Amarantus Bioscience Holdings, Inc. a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that their joint venture company, Breakthrough Diagnostics, Inc. has completed enrollment of its ongoing clinical trial evaluating the relationship of Alzheimers blood diagnostic Lymphocyte Proliferation Test (LymPro Test) with amyloid PET neuroimaging at Leipzig University in Germany (the LymPro PET 2). Topline results are expected before the end of the first quarter of 2020.

Breakthrough completed a 20-subject clinical study (LymPro PET 1) in 2018 evaluating the correlation between LymPro scores and the diagnosis of Alzheimers disease, as confirmed with amyloid PET neuroimaging and other Alzheimers disease biomarkers. LymPro measures cell cycle dysregulation in peripheral lymphocytes. The top-line data, announced in July 2019, revealed a strong and statistically significant correlation between LymPro scores and amyloid PET neuroimaging cSUVR scores (r = -0.849; p = 0.00000216). Breakthroughs academic collaborators at the Leipzig University then expanded enrollment of that study to include an additional cohort of 20 subjects (LymPro PET 2) to confirm the strong relationship seen from LymPro PET 1. The data from both LymPro 1 and LymPro 2 will be published together in a peer-reviewed journal in 2020.

LymPro is a unique immune system-based Alzheimers blood test, said Dr. Herman Weiss, President & CEO of Todos. LymPro could prove to be a major breakthrough for Alzheimers disease diagnosis by measuring cell cycle dysregulation and amyloid, together, conveniently as part of a blood workup in routine clinical practice. The therapeutic field in Alzheimers has begun to see some renewed hope based upon recent Aducanumab data announced by Biogen that is directly related to the amyloid hypothesis, as well as conditional approval by the National Medical Products Administration in China for the first new Alzheimers drug in over 20 years, called Oligomannate from Shanghai Green Valley Pharmaceuticals, that is based on gut-brain biology of the microbiome and its effects on the immune system. We believe this renewed optimism and broadening of pathophysiological hypotheses relevant to Alzheimers disease being evaluated in the clinic significantly increases the scope for LymPro pharma services collaborations and begins to refine LymPros clinical utility profile for primary care physicians as strategies to correct cell cycle dysregulation emerge.

About Alzheimer's DiseaseAccording to the Alzheimer's Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease. Over 500,000 patients are diagnosed annually, with nearly one-in-eight older Americans affected by the disease. Alzheimer's disease is the third leading cause of death in the United States. The cost of unpaid care in the United States is estimated at over $210 billion annually. Total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. Alzheimer's expenditures in the United States are expected to exceed $1.2 trillion by 2050. There is no cure or effective treatment for Alzheimer's disease. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer's by 2050.

About Dr. Arendt's Research at Leipzig UniversityDr. Thomas Arendt is Professor of Neuroscience at Leipzig University where he runs the Paul Flechsig Institute of Brain Research. He has a 30-year record in R&D of therapeutic and diagnostic strategies of neurodegenerative disorders and made several seminal contributions to therapeutic concepts of Alzheimer's disease, including stem cell therapy and modulating tumor suppressor genes. In the early 1980's, he was involved in identifying the degeneration of the cholinergic system in Alzheimer's disease laying the basis for today's only available treatment. He is one of the pioneers of the "cell-cycle theory" of Alzheimer's disease, which he developed towards a diagnostic and therapeutic concept.

About Breakthrough Diagnostics, Inc.Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd. (19.99%). Breakthrough has been assigned the intellectual property and other rights to the LymPro Test, a diagnostic blood test for Alzheimers disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical has provided Amarantus with notice of Todos decision to exercise its exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.

The Lymphocyte Proliferation Test (LymPro Test) determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as surrogates for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

About Todos Medical Ltd.Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancers influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The companys two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test, a blood test for diagnosing Alzheimers disease.

For more information, the content of which is not part of this press release, please visit http://www.todosmedical.com

About Amarantus Bioscience Holdings, Inc.Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. The Companys 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd., has licensed intellectual property rights to the Alzheimers blood diagnostic LymPro Test from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise and Parkinsons diagnostic NuroPro. Amarantus entered into a joint venture agreement with Todos Medical, Ltd. to advance diagnostic screening assets and Todos has exercised its exclusive option to acquire Amarantus remaining ownership in Breakthrough in exchange for approximately 50% ownership of Todos. The transaction is expected close before the end of the first quarter of 2020. Amarantus also owns approximately 30% of the common shares of Avant Diagnostics, Inc., a healthcare data-generating technology company that specializes in biomarker assay services that target multiple areas of oncology. Avant provides precision oncology data through its TheraLink assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders, initially for breast cancer, to over 70 FDA-approved drug treatments.

AMBS 50%-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimers aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired Cutanogen Corporation from Lonza Group in 2015. Cutanogen is preparing for pivotal studies with Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative medicine-based, autologous full-thickness skin graft technology originally developed by the Shriners Hospital that can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications. AMBS wholly-owned subsidiary, MANF Therapeutics Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics is developing MANF-based products as treatments for ophthalmological disorders such as Wolfram Syndrome, Retinitis Pigmentosa and Glaucoma, as well as neurodegenerative diseases such as Parkinsons disease. MANF was discovered by the Companys Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS proprietary discovery engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. Amarantus has entered into a binding letter of intent to license the therapeutic assets from Elto Pharma, Cutanogen and MANF Therapeutics to Emerald Organic Products.

Forward-looking StatementsCertain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

2019 GlobeNewswire, Inc. All Rights Reserved.

SOURCE: Todos Medical Ltd.

Read more from the original source:
Todos And Amarantus JV Announces Full Enrollment For Clinical Trial Of LymPro Alzheimer's Blood Test Relationship With Amyloid PET - Laboratory...

The FDA recently granted its regenerative medicine advanced therapy designation to a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma an indication that the therapy, called CT053, can address an unmet medical need for patients with the disease.

Read a summary of the FDAs decision and all of lasts weeks top stories in hematology/oncology.

FDA grants CAR T-cell therapy regenerative medicine advanced therapy designation for multiple myeloma

The FDA has granted its regenerative medicine advanced therapy designation to CT053, a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma. Read more.

National Comprehensive Cancer Network's off-label cancer treatment recommendations constitute a problem

HemOnc Today spoke with Vinay K. Prasad, MD, MPH, about recommendations from the National Comprehensive Cancer Network for off-label cancer therapies, which he says are based on little or no evidence. Read more.

Study suggests National Comprehensive Cancer Network off-label recommendations valid based on available evidence

HemOnc Today also spoke with Razelle Kurzrock, MD, who contends that recommendations from the National Comprehensive Cancer Network for off-label cancer therapies are valid. Read more.

Studies show oncologists can adapt quickly to new evidence

As emerging cancer treatments continue to be approved at a rapid pace, published findings suggest that oncologists, who are reputed to be slow to change, can quickly adjust practice based on post-approval safety data or when novel cancer therapies enter the market. Read more.

Access to care among critical priorities for American Cancer Societys new chief medical, scientific officer

William G. Cance, MD, has begun his new role as American Cancer Societys chief medical and scientific officer. In an interview with HemOnc Today, Cance spoke about his priorities in his new role, the challenges he anticipates and how he hopes to meet them and his expectations for the oncology field in the coming years. Read more.

Original post:
FDA acts on CAR T-cell therapy, other top stories in hematology/oncology - Healio

Doris A. Taylors so-called replacement ghost heart suggests something otherworldly, but the eerie-looking form is far from an apparition. Its an innovative approach to organ transplantation that has inspired many in the medical community and at least one artist.

The Texas researchers process piggybacks on natures sophisticated design. Together she and a team of researchers strip cells off human and animal cadaver hearts with a soapy solution, leaving ghostly white protein shells that retain the form of the organ. They inject them with a patients blood or bone-marrow stem cells, and the ghost hearts act as scaffolding on which the newly introduced cells can slowly transform into a beating muscle.

What we said was, Wouldnt it be really cool if we could wash the sick cells out and put the healthy cells back in? said Taylor, director of Regenerative Medicine Research and director of the Center for Cell and Organ Biotechnology at the Texas Heart Institute, during a recent talk at the Radcliffe Institute for Advanced Study.

The hope is that one day these regenerated hearts will resolve the most challenging issues transplant patients currently face: the lack of a permanent artificial replacement, concerns about rejection, and the shortage of viable donor hearts.

Taylors efforts are driving what could become a revolution in organ transplants, and they have sparked the creativity of transdisciplinary artist Dario Robleto, whose latest work, on view at the Johnson-Kulukundis Family Gallery in Radcliffes Byerly Hall, recreates in images and sounds the original pulse wave of the heart first captured in visual form by scientists in the 1900s. Robleto and Taylor, longtime friends and Texas residents, explored those connections during Mondays Radcliffe discussion, which was moderated by Jennifer Roberts, Elizabeth Cary Agassiz Professor of the Humanities.

Robletos exhibit, Unknown and Solitary Seas, touches on the overlap between the medical mysteries and workings of the vascular pump, and the metaphor for the heart as the emotional center of the soul. It includes a video installation that features recreated sounds of a beating heart from the 19th century, reconstructed images of how the earliest pulse waves first appeared on the page, and a series of heart waveform sculptures in brass-plated stainless steel.

Roberts said that with his work, Robleto acknowledges the pulse waves promise, their profundity, their scientific value, but he also reclaims some of their ambiguity and asks us to wonder whether we can or should accept that these waveforms have escaped the realms of art, culture, and emotional communication.

Taylor similarly views her work as a blend of the scientific and the human. It transcends complicated, complex science, she says, in that her ghost hearts require a kind of passion, commitment, care, attention, and nurturing similar to whats required by a small child. Its really about building hearts at the emotional, mental, spiritual, and physical level that I think is going to get them to work, she said.

For Robleto, big ideas, like the creation of a new human heart, require multiple perspectives.

The artist called Taylors work one of the most fascinating and definitely one of the most emotional things Ive ever seen. As an object, he added, the ghost heart is stunningly beautiful but it also raises questions about the self, identity, emotion, the notions of form and where memory is truly held, questions he thinks artists can help address. He cited two of the nations earliest heart transplants, after which the patients wives asked their husbands, who had received donor hearts, if they still loved them.

Taylors work, Robleto said, is right at the edge of identity and materiality and so when the day comes when someone says the first ghost heart transplant I think we will have a similar moment where perhaps we will be forced to re-evaluate what we ask from our heart metaphor.

Dario Robletos Unknown and Solitary Seas is on view in Byerly Halls Johnson-Kulukundis Family Gallery through Jan. 18, 2020.

Follow this link:
An artist and a transplant researcher discuss the heart - Harvard Gazette

Global Regenerative Group, a proven company in the field of medicine and innovation, is pleased to announce partnerships with Remodem and Aurafix.

Boca Raton, FL, November 09, 2019 --(PR.com)-- Remodem is a company offering an innovative product with an interesting mechanism of action.

A new molecule, external inorganic gel liquid magnet, has been developed using a combination of silica, calcium chloride, and tetrahydropiperine, which have a very high water holding capacity. External inorganic gel liquid magnet is a new generation, patented molecular structure with a high hydrophilic feature that is not likely to be absorbed into the skin.

It is applied as a layer with a minimum thickness of 3mm to cover the entire edema area that occurs after tissue trauma. The area of application is then covered with sterile bandage for twelve hours.

This unique product, Remodem Superficial Swelling Reducing Gel, helps to reduce swelling and discoloration that occur due to sprain, muscle strain, trauma, sports injury, as well as aesthetic and plastic surgeries. As Remodem is used in many fields of medicine, this partnership will bring the Remodem product line to GRGs network of professionals around the world and allow the company to reach its full potential.

With its beginnings in a small workshop, Aurafix has continually improved itself by paying attention to the importance of quality, workmanship, and superior service as well as investing in human capital and technology. Aurafix has been an application center in the fields of orthesis, prosthesis and rehabilitation since 2002.

The Aurafix products are focused in three areas: Orthopedics, Liposuction, and Compression. All of the products manufactured are flawlessly delivered to users using a strict quality control process that ensures accordance with the relevant standards:

- Adhesive VELCRO surfaces provide comfort and ease of use.- Flexible neoprene material provides ease of movement and a warming, soothing effect along with high strength. Increased body temperature accelerates the healing process by increasing blood circulation.-A flexible cotton fabric with high air permeability. The flexible structure provides the required support and comfort by wrapping the body.

The company continues to grow and operate as a leading brand name in the domestic market. By partnering with Global Regenerative Group, Aurafix will become a worldwide recognized brand.

Aurafix offers 240 different Orthopedic products, 50 Liposuction, and 50 Compression products.

For full product list please see the catalogues:

- Aurafix Orthopedics- Aurafix Liposuction- Aurafix Compression

Of the agreement, the President of Global Regenerative Group, Randolph Beimel said, The Global Regenerative Group is a medical community comprised of doctors, scientists, hospital administrators, businessmen, and entrepreneurs in more than 35 countries; all focused on developing the newest and most innovative products to provide the best possible outcomes for the patient. The GRG relationships around the world give us the opportunity to identify the highest quality products in a particular country and distribute them globally. The international launch of the Aurafix and Remodem product lines will offer patients on four continents the same benefits that patients in Turkey have experienced for many years.

Global Regenerative Group is a fast-growing company, collaborating with specialists and clinics around the world, with the primary purpose of delivering innovative medical care to the patient. During the last decade the company has developed extensive experience in the most advanced medical device industries. Recently, the company's emphasis has been focused exclusively on Regenerative Medicine, such as stem cell technologies, products, and therapies.

Global Regenerative Trade, a subsidiary of Global Regenerative Group, is dedicated to bringing science in practice through product development. Our main mission is supporting and accelerating the healing process following medical treatment by enhancing the bodys own capabilities. Global Regenerative Trade serves as a hub, bringing together products used in various fields of medicine. Using cumulative knowledge and expertise in the field of Regenerative medicine, we develop products which enhance the quality of life of patients and are more user-friendly for doctors.

Contact Information:Global Regenerative GroupRandy Beimel954-778-2581Contact via Emailglobalregenerative.group

Read the full story here: https://www.pr.com/press-release/798942

Press Release Distributed by PR.com

The rest is here:
Global Regenerative Group Enters Into Distribution Partnership with Aurafix & Remodem - Benzinga

WILMINGTON Cucalorus Connect, held Nov. 14 and 15 in Wilmington, explores the intersection between creativity, technology, and humanity, this year with a different structure and emphasis on innovative healthcare technology.

The two-day gathering brings people together to discuss what kind of future we could build if we use innovation and technology to expand our sense of humanity. The conference features leading thinkers on health, finance, startups, coastal resilience, racial justice.

This year says Dan Brawley, director of Cucalorus, the structure of the event has changed. Its more holistic and less compartmentalized. As it evolved, weve gotten more clear about the type of experience we wanted to create for people.

Dan Brawley, director of Cucalorus. Photo by R Wright.

Though it began as primarily a business conference, It isnt just a conference about how to make money, Brawley said. Its a conference about how to make the world a better place using technology and creativity.

Nick Adkins, co-founder of Pinksocks Life, a nonprofit organization focused on promoting human connection around the world, will deliver the keynote address on The Power of Connection

The pinksocks movement empowers people from all walks of life to connect with anyone, anywhere, by creating a global tribe of pinksocks-wearing people who are focused on empathy, caring and love. The movement has been decommoditized from its beginning in 2015 all pinksocks are gifts. Every connection made between the gift giver and recipient is based on an authentic connection, not a transaction.

Pinksocks movement founder Nick Adkins keynotes Cucalorus Connect this year. Photo courtesy of Cucalorus.

There is a lot of focus in the program on the future of healthcare with an emphasis on helping people discover new ways to use innovation and technology. How mind-bending it is that you can improve your health in ways we never imagined, said Brawley.

One of the sessions Brawley finds most interesting is Marie Johnsons Digital Humans in Healthcare. Johnson will talk about what she sees as her moon shot, where digital humans are part of an augmented health ecosystem: helping patients and reducing staff burnout.

The digital avatars talk to you all the time and have to be real and authentic, notes Brawley. Its challenging, he said, Ten times harder than making a movie.

Johnson, an Australian entrepreneur, conceived and led the global co-design effort with people with disabilities to deliver Nadia the first AI digital human for service delivery. This work sparked a global industry and appetite for AI-powered digital humans.

An AI Digital Human Cardiac Coach is Johnsons current effort. Its day to day indicators may even be able to predict when a patient will suffer a heart attack. Its a wildly creative app that promises to change things, Brawley said. Some of the most creative people in the world are computer programmers. The things they do with ones and zeroes are incredible.

Film explores regenerative medicine

Other health-focused sessions include Regenerative Medicine in the film Five Minutes. Five Minutes is a film about Baptiste Touissants recovery when a suicide bomber detonated only feet from him in Afghanistan and his hope for regenerative medicine (RM) for U.S. soldiers.

RM promises a future where doctors, using a soldiers own cells, rebuild genitalia and reconstruct arms and legs blown apart by shrapnel. The animated narrative film is a five-year effort directed, produced and edited by Wake Forest University faculty. Wake Forest is a leader in RM research.

More Than Words: how visuals can help us heal healthcare, examines how words alone cant efficiently explain bodily sensations or lifetime journeys. They cant sufficiently show emotions or trauma. As a result, patients and doctors often dont understand each other, and our broken healthcare system bumbles along. This session will feature stories from a doctor and a patient who have each discovered new ways of communicating using visuals and drawing.

Apart from the healthcare focus, one of the most interesting sessions is Youre in the matrix and just dont know it. Two University of North Carolina at Wilmington professors discuss the possibility that we may all be living in the paradigm developed in The Matrix movie franchise.

Dr. Curry Guinn and Dr. Julian Keith, UNCW professors, will discuss the possibility that were in the matrix and dont know it. Photo by R Wright.

The conference does still cover hot business topics, from the Influence of Design, to Martech. Martech is the latest buzzword in the marketing industry. It refers to any technology that a marketer can use to reach a potential customerfrom social media scheduling platforms to email.

Thesession highlights how to use Martech in all phases of marketing and PR campaigns from strategic planning to implementation and results measurement with the goal to create efficient and effective campaigns.

Another session looks at Blockchain technology, contrasting whats hot vs. whats hype.

Image courtesy of Cucalorus

The 10X10 Challenge returns this year. Ten entrepreneurs are paired with 10 filmmakers and challenged to make a three-minute promo video in five days. The films are shown on Sunday. The Rocket Pitch event is a fast-paced pitch competition. startups go head-to-head with just 90 seconds and one slide to capture audience votes.

BarMembership

Brandon Noel

An all-in-one solution compliance platform for North Carolina bars to manage members.

GreenStream Technologies

Karen Lindquist

Monitors and reports conditions in the environment with an end-to-end solution for floods in urban, suburban, rural and even remote environments.

Language Corpus

Reid Wilson

A subscription-based offering for intermediate and advanced language learners to understand what people are saying to them, around them and about them.

Survei

David Stone

Apartment complexes share what is known as a competitive portfolio. Survei speeds up the process, while also increasing data reliability.

Safe and Sound

Elizabeth Baker, Stacey Kolomer

A disaster management mobile app which informs managers of colleagues locations in a crisis, while maintaining security and privacy for a healthy work/life balance not given when using social media.

Skilly-do

Claire Holroyd

A toolkit proven in the real world with thousands of teachers and children to make the most of childs early development and learning through play.

See the 10X20 and Rocket pitch session description for links to the companies.

Read the original:
Cucalorus Connect Conference Nov. 14-15 explores intersection of creativity and technology - WRAL Tech Wire

A new type of micromotor has been developed. Directed by magnets and powered by ultrasound, these micromotors are capable of traveling across microscopic particles and cells in very crowded areas without causing any damage.

These microswimmers provide a new way to manipulate single particles with precise control and in three dimensions, without having to do special sample preparation, labeling, surface modification, said Joseph Wang, a professor of nanoengineering at University of California San Diego (USCD), in a UCSD press release.

Wang, Thomas Mallouk, a professor of chemistry at the University of Pennsylvania, and Wei Wang, professor of materials science and engineering at Harbin Institute of Technology, are credited as senior authors of a paper detailing the development of these micromotors. The study was published on Oct. 25 in Science Advances.

Researchers tested the technology by moving HeLa cells the oldest and most commonly used cell line for scientific research and silica particles in aqueous media with micromotors. They accomplished this task without damaging nearby particles and cells. In one test, the researchers were able to create letters by pushing particles with the micromotors. In another, they exerted control over the micromotors, making them climb up microscopic blocks and stairs. This test demonstrated that they were capable of navigating over three-dimensional objects.

The micromotors are essentially gold-coated hollow polymer structures that are shaped like a half capsule. Within the body of the micromotor is a tiny magnetic nickel nanoparticle, allowing them to be steered with magnets. The inside surface is treated so it can repel water, so when the micromotor is submerged in water, an air bubble is trapped inside the device. This trapped bubble is integral to the functioning of the micromotor, as it allows the micromotor to respond to ultrasound. Upon receiving ultrasound waves, the trapped bubble begins to oscillate, forming forces that give it an initial push to movement. By applying an external magnetic field, it can move continuously, while altering the direction of the field allows researchers to control the speed and trajectory of the micromotors.

We have a lot of control over the motion, unlike a chemically fueled micromotor that relies on random motion to reach its target, said Fernando Soto, a nanoengineering Ph.D. student studying at UC San Diego. Also, ultrasound and magnets are biocompatible, making this micromotor system attractive for use in biological applications.

The authors plan on making improvements to the micromotors in the coming years. For example, they want to make them more biocompatible using biodegradable polymers and a magnetic material that is less toxic, such as iron oxide. Thanks to this technology, the researchers have opened new possibilities for nanomedicine, tissue engineering, targeted drug delivery, regenerative medicine, and other applications in the field of biochemistry.

See original here:
Micromotors move single cells using magnets and ultrasound - CMU The Tartan Online

I cant stress enough the value of having the Specialty Med Training team work with me, side by side, teaching me specific techniques, proven protocols and pearls of how to successfully implement them into my practice offering... Elvira Wright, SMT Client

DELRAY BEACH, Fla. (PRWEB) November 08, 2019

Specialty Med Training, one of the nations largest training, research and marketing company has added a combination cellular hair regrowth course to its extensive library of regenerative medicine educational programs. This latest course, designed to instruct and certify practitioners on how to combine regenerative therapies including platelet rich plasma (PRP), micro-needling, pharmaceutical peptides, photobiomodulation, and nutraceuticals for cellular hair regrowth. The comprehensive course is offered as an online video demonstrated course broken into three modules or trainees have the option for a clinical educator to travel to the clinic to teach the doctor and the staff how to successful perform and implement the therapies into their practice offering.

I cant stress enough the value of having the Specialty Med Training team work with me, side by side, teaching me specific techniques, proven protocols and pearls of how to successfully implement them into my practice offering. The best part- I didnt have to leave my office, my schedule was not disrupted and Im certain I cut the learning curve in half! Elvira Wright, SMT Client

Attendees with gain a full understanding of the pathophysiology of hair loss, the most common causes, as well as other less common causes for hair loss and hair thinning. The course covers the history of the therapies, mechanism of action, review of articles published, and even how to talk to your patients and staff. The video portion demonstrates each therapy in the combination protocol in great detail.

In addition to understanding how to prep patients, process biologics and apply these therapies by watching live procedures on actual patients, Specialty MED training registrants will receive all the tools necessary to successfully implement regenerative procedures into their clinical practice quickly and efficiently.

The training courses are intended for all practitioners; those with no experience using regenerative therapies to those with significant experience. Upon final completion of the online course, graduates will be certified by Specialty MED Training.

Training program fees range from $599 - $3,995.

To register for training, visit specialtymedtraining.com or call 561-408-7248.

About Specialty Med TrainingSpecialty MED Training (SMT) is a national training, research and marketing company; dedicated to helping physicians bring the latest regenerative therapies and treatment options to their patients. They are actively building a national network of leading providers committed to the ethical and responsible advancement of the use of regenerative therapies in clinical practice.

Share article on social media or email:

More:
Specialty MED Launches Online Training Course for Regenerative Hair Regrowth Combination Therapy Protocols for Cellular Hair Regrowth - PR Web

HAIFA, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the RESTORE Consortium is hosting its 1st Advanced Therapies Science Meeting (ATSM), which is being held November 25-26, 2019 in Berlin. As a leading member of the large-scale research initiative, Pluristem, along with additional respected members, is committed to accelerating the availability of advanced therapies to all those in need, a main motivation standing behind RESTORE.

Led by Charit-Universittsmedizin Berlin, and coordinated by Professor Hans-Dieter Volk from the BIH-Center for Regenerative Therapies in Berlin, RESTORE aims to promote groundbreaking research, drive Europe to the forefront in advanced therapies and deliver a pipeline of potentially transformative cures to patients in need. Advanced Therapies are a potential game changer in health care, aiming to shift our focus from chronic treatment of disease to regeneration of health, said Prof. Volk. We are determined to translate promising research findings into safe therapies, and we are working across disciplines and national borders in order to achieve this goal. The 1st Advanced Therapies Science Meeting provides the opportunity to discuss the still numerous obstacles in the way of implementing these promising therapies in routine clinical care.

This initiative may hold the key for changing the approach towards medicine in Europe, and advancing solutions for patients in need, said Zami Aberman, Executive Chairman of Pluristem. The European Commission is poised to make a significant investment of up to 1 billion in a consortium of companies that can drive forward the development of novel regenerative therapies, and we are pleased to be a leading part in this effort. Given our proprietary cell manufacturing technology and broad, late-stage pipeline, we believe we can play a key role toward making the transforming promise of advanced therapies into a reality.

The 1st ATSM will bring together experts from industry, patient organizations and academia to discuss the challenges within the field of advanced therapies, which include gene and cell therapies and tissue-engineering approaches. The ATSM is focused on trying to drive forward a concerted interdisciplinary effort, making use of science, infrastructure and funding within Europe to make regenerative therapies available to the broadest possible patient population.

The two-day program will include talks from Nobel Prize winner Ada Yonath (Director of Weizmann Institute of Science, Israel), Michele De Luca (University of Modena, Italy), Timothy OBrien (National University of Ireland, Galway, Ireland), Maksim Mamonkin (Baylor College of Medicine, USA), Manuela Gomes (University of Minho, Portugal) and others.

RESTORE partners include the Charit Universittsmedizin Berlin and Berlin Institute of Health (Germany), the University of Zurich (Switzerland), Cell and Gene Therapy Catapult (United Kingdom), TissUse GmbH (Germany), Pluristem (Israel), Miltenyi Biotec GmbH (Germany), INSERM Institut National de la Sant et de la Recherche (France), Innovation Acta S.r.l. (Italy), Fondazione Telethon Milan (Italy), and the University of Minho (Portugal).

About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Story continues

Safe Harbor StatementThis press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the potential for the RESTORE Consortium to receive up to a 1 billion award by the European Commission and the timing of the potential award, that RESTOREs aim is to promote groundbreaking research, drive Europe to the forefront in advanced therapies and deliver a pipeline of potentially transformative cures to patients in need, that RESTORE and the 1st ATSM may hold the key for changing the approach towards medicine in Europe, and advancing solutions for patients in need, and its belief that given its proprietary cell manufacturing technology and broad, late-stage pipeline, it believes it can play a key role toward making the transforming promise of advanced therapies into a reality. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

See more here:
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare -...

WASHINGTON, D.C., Nov. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM) today released its most recent quarterly sector report, offering an in-depth look at cell therapy, gene therapy, tissue engineering, and broader global regenerative medicine sector trends and metrics in the third quarter of 2019.

By further curating information provided by ARMs data partner Informa, the quarterly sector report details industry-specific statistics compiled from 959 cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARMs current strategic priorities.

Amanda Micklus, a senior consultant for Pharma Intelligence at Informa, provided an overview of the commercial, clinical, and regulatory environment in the third quarter of 2019. The report also features commentary from founding members of ARM in honor of the organizations 10-year anniversary. Excerpts from panels at ARMs 2019 Meeting on the Mesa included in the report highlight the continued progress and innovation in the sector.

Highlighted findings from the Q3 2019 data report include:

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trials by phase, and significant clinical data events.

The report isavailable online here, with interactive data and downloadable graphics from the reportavailable here. For more information, please visitwww.alliancerm.orgor contact Lyndsey Scull at lscull@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Lyndsey Scull202 213 7086lscull@alliancerm.org

See more here:
The Alliance for Regenerative Medicine Releases Q3 2019 Sector Report, Highlighting Industry Trends and Metrics - BioSpace